How much funding has Nilo Therapeutics raised?

Nilo Therapeutics has raised $101.0M in total funding, most recently a series a round.

Who are Nilo Therapeutics's investors?

Nilo Therapeutics's investors include The Column Group, DCVC (Data Collab), Lux Capital, Gates Foundation, Alexandria Venture Investments.

When was Nilo Therapeutics founded?

Nilo Therapeutics was founded in 2024.

Where is Nilo Therapeutics headquartered?

Nilo Therapeutics is headquartered in New York City, United States.

What industry is Nilo Therapeutics in?

Nilo Therapeutics operates in Biotech, Healthcare.

How many employees does Nilo Therapeutics have?

Nilo Therapeutics has 1-10 employees.

Nilo Therapeutics

New York City, United States · Founded 2024 · $101.0M raised

Biotech

Healthcare

Headquarters: New York City
Employees: 1–10
Founded: 2024
Business Model: B2B

Website: nilotx.com
Total Funding: $101.0M
Last Round: $101.0M Series AOct 2025
Rounds: 1

About

Nilo Therapeutics is an early-stage biotech company developing a new class of medicines for autoimmune and inflammatory diseases by targeting the body's neural circuits that regulate immune function. Founded in 2024 by scientists from Columbia University and Yale, the company's approach harnesses neuronal-circuit modulation to restore immune homeostasis, offering a differentiated mechanism compared to existing biologics. The company launched with a $101M Series A and is headquartered in New York City.

Summary

Nilo Therapeutics is a Biotech company based in New York City, United States, founded in 2024. It has raised $101.0M in total across 1 round, most recently a $101.0M Series A round in Oct 2025. Investors include The Column Group, DCVC (Data Collab) and Lux Capital.